The aim of our study was to investigate the migratory response of isolated neutrophils by specific activation with C5a. Chemotaxis to the complement independent chemoattractant casein has previously been investigated in IBD.57 This
Hypercatabolism of complement has been revealed in chronic inflammatory bowel disease (IBD) by studies of the third component C3, which occupies a key position in cascade reactions involving both the classical and alternative pathway.' An increased fractional catabolic rate of this component2 appears to be associated with raised concentrations of circulating C3 split products.3 Furthermore, indirect evidence for continuing activation of complement in IBD has been forwarded by investigations of immunoconglutinins. Such antibodies to activated complement components have been shown in increasing titres with increasing length of disease history.4 Activation of complement in vitro leads to utilisation of C3, correlating positively to release of the split product C5a from the native complement component C5 in normal subjects and IBD patients.5 These results are consistent with an activation of neutrophil functions by C5a in IBD patients.
The aim of our study was to investigate the migratory response of isolated neutrophils by specific activation with C5a. Chemotaxis to the complement independent chemoattractant casein has previously been investigated in IBD.57 This non-physiologic activator was included. in all the present tests to study the basic cell function.
Methods

PATIENTS
Consecutive outpatients, 15 with Crohn's disease and 15 with ulcerative colitis were studied. Patients who had been treated medically within the three preceding months were excluded. The diagnostic criteria applied have previously been published.8
Eight of the Crohn's disease patients had the diagnosis confirmed by histology. None (Fig. 3) . Spontaneous, non-activated motility ranged from 20-43 ,m/30 min and did not show differences between patients and controls. Significant decreases of sensitivity and peak response to C5a were found in patients in complete clinical remission and in active stages of chronic inflammatory bowel disease (p<005) ( Table 2) . A trend for a more severely depressed peak response in active stages of the disease did not reach statistical significance (p>0.10). Data for patients with Crohn's disease and ulcerative colitis showed no differences and were pooled in Table 2 .
Chemotaxis to casein did not differ between healthy volunteers (median 75 ,um/60 min), patients with Crohn's disease (median 77 ,m/60 min), and ulcerative colitis (median 77 ,um/60 min) (p>0.10) (Fig. 4) .
Dose response curves and responses to casein were assessed by the leading front method. This parameter of neutrophil function may not be representative for the whole population of migrating Cell suspensions prepared for chemotaxis contained approximately 70% neutrophils, and the recovery of neutrophils was 70% (Table 3) .
Discussion
Investigation of phagocytic cell function in IBD patients may be important for understanding the pathogenesis of the disease. In chronic granulomatous disease a dysfunction of neutrophils can produce histologic changes of the gut closely resembling those seen in Crohn's disease. 16 Previous investigations of neutrophil chemotaxis in IBD have shown an essentially normal response to the nonphysiologic attractant casein.5-7 The present study confirms this finding showing a normal basic cell function but has revealed specific changes of neutrophil activation by complement. Analysis of dose response curves showed that sensitivity to C5a was decreased by a factor of two in patients both with Crohn's disease and ulcerative colitis. This abnormality could not be overcome by increasing the concentration of activator, leading to a depression of responses. Peak migration rates obtained by the panel of C5a concentrations tested were furthermore similarly decreased in both groups of patients. 4 Chemotaxis to casein did not differ between groups ofpatients and healthy volunteers (p>OJ10). 
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